This trend was not verified by the GDSC2 dataset for dasatinib; however, median IC50 values of some KIT‐targeting drugs (pazopanib, sunitinib, tivozanib) were lowest in SCLC‐P cell lines, as well as SCLC‐Y subtype's higher resistance to vorinostat could be validated (Figure S9b). This evidence concerns the gene KIT and small cell lung carcinoma.